CTSO
Cytosorbents Corporation
NasdaqCMUSDEQUITY
DELAYED
Last price
0.36
▲ 0.05 (16.23%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
0.32
Prev close
0.31
Day high
0.38
Day low
0.31
Volume
325.76K
Market cap
—
P/E (TTM)
—
52W range
0.30 – 1.04
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
-7.50%
-6.1%
1M
+2.49%
-1.2%
3M
-19.57%
-22.7%
6M
-42.19%
-53.3%
YTD
-42.10%
-54.4%
1Y
-58.61%
-78.6%
3Y
-86.25%
-160.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $37.06M | $35.59M | $31.08M | $29.36M | +4.1% |
| Operating revenue | $37.06M | $35.59M | $31.08M | $29.36M | +4.1% |
| Cost of revenue | $10.57M | $10.71M | $9.13M | $13.96M | -1.3% |
| Gross profit | $26.49M | $24.89M | $21.95M | $15.40M | +6.4% |
| Research & development | $5.08M | $7.61M | $15.59M | $15.12M | -33.2% |
| Selling, general & admin | $35.65M | $33.73M | $38.31M | $37.14M | +5.7% |
| Total operating expense | $40.73M | $41.34M | $53.90M | $46.93M | -1.5% |
| Operating income | -$14.24M | -$16.45M | -$31.95M | -$31.52M | +13.5% |
| Net interest income | -$2.61M | -$1.40M | -$157.89K | $132.60K | -86.7% |
| Pre-tax income | -$8.60M | -$22.41M | -$30.06M | -$33.91M | +61.6% |
| Tax provision | -$401.00K | -$1.69M | -$813.74K | -$1.09M | +76.3% |
| Net income | -$8.20M | -$20.72M | -$29.25M | -$32.81M | +60.4% |
| Net income to common | -$8.20M | -$20.72M | -$29.25M | -$32.81M | +60.4% |
| Basic EPS | -0.13 | -0.38 | -0.65 | -0.75 | +65.8% |
| Diluted EPS | -0.13 | -0.38 | -0.65 | -0.75 | +65.8% |
| EBIT | -$5.99M | -$21.01M | -$29.90M | -$31.52M | +71.5% |
| EBITDA | -$4.36M | -$19.27M | -$27.88M | -$30.39M | +77.4% |
| Basic shares | 62.23M | 54.43M | 44.66M | 43.79M | +14.3% |
| Diluted shares | 62.23M | 54.43M | 44.66M | 43.79M | +14.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $6.25M | $3.28M | $14.13M | $22.14M | +90.5% |
| Cash & short-term investments | $6.25M | $3.28M | $14.13M | $22.14M | +90.5% |
| Accounts receivable | $7.55M | $7.32M | $6.06M | $5.66M | +3.1% |
| Inventory | $5.28M | $2.73M | $3.38M | $3.46M | +93.2% |
| Total current assets | $20.63M | $21.60M | $25.40M | $33.76M | -4.5% |
| Property, plant & equipment | $18.75M | $20.51M | $22.12M | $23.35M | -8.6% |
| Goodwill & intangibles | $3.23M | $3.72M | $3.91M | $4.39M | -13.3% |
| Total assets | $44.18M | $47.37M | $52.96M | $63.23M | -6.7% |
| Total current liabilities | $9.71M | $9.82M | $14.04M | $9.71M | -1.2% |
| Current debt | — | — | $2.50M | — | — |
| Long-term debt | $16.67M | $14.00M | $2.54M | $5.00M | +19.1% |
| Total debt | $29.11M | $26.89M | $18.31M | $18.25M | +8.2% |
| Total liabilities | $38.28M | $36.27M | $29.48M | $27.86M | +5.6% |
| Retained earnings | -$312.21M | -$304.01M | -$283.29M | -$254.00M | -2.7% |
| Shareholder equity | $5.90M | $11.11M | $23.48M | $35.37M | -46.9% |
| Working capital | $10.93M | $11.78M | $11.36M | $24.05M | -7.3% |
| Net tangible assets | $2.68M | $7.39M | $19.57M | $30.98M | -63.8% |
| Shares issued | 62.80M | 55.10M | 54.51M | 43.85M | +14.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$8.20M | -$20.72M | -$29.25M | -$32.81M | — | +60.4% |
| Depreciation & amortisation | $1.63M | $1.74M | $2.02M | $1.13M | — | -6.5% |
| Stock-based compensation | $2.77M | $3.76M | $4.16M | $3.80M | — | -26.5% |
| Change in working capital | -$1.03M | -$4.38M | $2.65M | -$3.56M | — | +76.5% |
| Operating cash flow | -$12.38M | -$14.43M | -$21.66M | -$28.23M | — | +14.2% |
| Capital expenditure | -$491.00K | -$669.00K | -$936.24K | -$6.46M | — | +26.6% |
| Investing cash flow | -$415.00K | -$669.00K | -$936.24K | -$6.46M | — | +38.0% |
| Share buybacks | — | — | — | -$40.36K | -$90.00K | — |
| Financing cash flow | $9.31M | $9.33M | $14.47M | $4.96M | — | -0.2% |
| Free cash flow | -$12.87M | -$15.10M | -$22.59M | -$34.69M | — | +14.8% |
| End cash position | $7.77M | $9.76M | $15.62M | $23.83M | — | -20.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $9.63M | $8.86M | $9.23M | $9.48M | $9.62M | — | +8.7% |
| Operating revenue | $9.63M | $8.86M | $9.23M | $9.48M | $9.62M | — | +8.7% |
| Cost of revenue | $2.58M | $2.73M | $2.43M | $2.82M | $2.80M | — | -5.5% |
| Gross profit | $7.05M | $6.13M | $6.80M | $6.67M | $6.81M | — | +15.0% |
| Research & development | $1.45M | $1.02M | $1.24M | $918.00K | $1.26M | — | +41.8% |
| Selling, general & admin | $7.96M | $8.15M | $9.44M | $8.61M | $9.17M | — | -2.3% |
| Total operating expense | $9.42M | $9.17M | $10.68M | $9.53M | $10.43M | — | +2.6% |
| Operating income | -$2.37M | -$3.04M | -$3.88M | -$2.86M | -$3.62M | — | +22.2% |
| Net interest income | -$868.00K | -$857.00K | -$746.00K | -$645.00K | -$616.00K | — | -1.3% |
| Pre-tax income | -$4.42M | -$5.13M | -$5.50M | -$3.57M | $1.95M | — | +13.9% |
| Tax provision | — | — | $0 | -$401.00K | — | $0 | — |
| Net income | -$4.42M | -$5.13M | -$5.50M | -$3.17M | $1.95M | — | +13.9% |
| Net income to common | -$4.42M | -$5.13M | -$5.50M | -$3.17M | $1.95M | — | +13.9% |
| Basic EPS | -0.07 | -0.08 | -0.09 | -0.05 | 0.03 | — | +12.5% |
| Diluted EPS | -0.07 | -0.08 | -0.09 | -0.05 | 0.03 | — | +12.5% |
| EBIT | -$3.55M | -$4.27M | -$4.75M | -$2.93M | $2.56M | — | +16.9% |
| EBITDA | -$3.17M | -$3.90M | -$4.37M | -$2.52M | $3.00M | — | +18.6% |
| Basic shares | 62.81M | 62.74M | 62.80M | 62.75M | 62.61M | — | +0.1% |
| Diluted shares | 62.81M | 62.74M | 62.80M | 62.75M | 67.17M | — | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.41M | $4.81M | $6.25M | $7.54M | $10.20M | -8.3% |
| Cash & short-term investments | $4.41M | $4.81M | $6.25M | $7.54M | $10.20M | -8.3% |
| Accounts receivable | $6.79M | $7.15M | $7.55M | $7.43M | $7.74M | -5.1% |
| Inventory | $3.69M | $4.48M | $5.28M | $4.00M | $3.71M | -17.7% |
| Total current assets | $15.74M | $17.76M | $20.63M | $21.31M | $22.99M | -11.4% |
| Property, plant & equipment | $17.78M | $18.28M | $18.75M | $19.27M | $19.69M | -2.7% |
| Goodwill & intangibles | $2.86M | $2.95M | $3.23M | $3.59M | $3.74M | -3.0% |
| Total assets | $37.96M | $40.56M | $44.18M | $45.75M | $47.99M | -6.4% |
| Total current liabilities | $24.02M | $16.30M | $9.71M | $10.11M | $9.84M | +47.4% |
| Current debt | $14.15M | $6.65M | — | — | — | +112.9% |
| Long-term debt | $3.09M | $10.31M | $16.67M | $14.57M | $14.38M | -70.0% |
| Total debt | $29.43M | $29.28M | $29.11M | $27.14M | $27.06M | +0.5% |
| Total liabilities | $38.71M | $38.37M | $38.28M | $36.73M | $36.40M | +0.9% |
| Retained earnings | -$321.75M | -$317.34M | -$312.21M | -$306.71M | -$303.54M | -1.4% |
| Shareholder equity | -$751.00K | $2.19M | $5.90M | $9.02M | $11.59M | -134.2% |
| Working capital | -$8.29M | $1.45M | $10.93M | $11.20M | $13.14M | -669.9% |
| Net tangible assets | -$3.62M | -$758.00K | $2.68M | $5.43M | $7.85M | -376.9% |
| Shares issued | 62.84M | 62.73M | 62.80M | 62.79M | 62.61M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$4.42M | -$5.13M | -$5.50M | -$3.17M | $1.95M | — | +13.9% |
| Depreciation & amortisation | $376.00K | $376.00K | $385.00K | $401.00K | $440.00K | — | 0.0% |
| Stock-based compensation | $368.00K | $544.00K | $886.00K | $488.00K | $573.00K | — | -32.4% |
| Change in working capital | $1.59M | $1.25M | -$1.17M | -$734.00K | $1.26M | — | +26.9% |
| Operating cash flow | -$583.00K | -$1.16M | -$4.83M | -$2.58M | -$1.51M | — | +49.8% |
| Capital expenditure | -$52.00K | -$72.00K | -$367.00K | — | -$132.00K | -$47.00K | +27.8% |
| Investing cash flow | $7.00K | -$46.00K | -$291.00K | $55.00K | -$132.00K | — | +115.2% |
| Financing cash flow | $0 | $0 | $2.48M | $0 | $0 | — | — |
| Free cash flow | -$635.00K | -$1.23M | -$5.19M | -$2.52M | -$1.64M | — | +48.5% |
| End cash position | $5.93M | $6.33M | $7.77M | $9.06M | $11.73M | — | -6.3% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.36
-0.33% from price
SMA 20
0.37
+1.20% from price
SMA 50
0.39
-4.53% from price
SMA 100
0.47
-23.30% from price
SMA 200
0.58
-36.36% from price
EMA 12
0.36
-0.07% from price
EMA 26
0.37
-2.66% from price
EMA 50
0.40
-9.21% from price
RSI (14)
49.5
Neutral
MACD (12,26,9)
-0.01
Hist -0.00
ATR (14)
0.04
10.02% of price
Realised vol 30D
89.2%
Annualised
Bollinger upper
0.40
20, 2σ
Bollinger lower
0.33
20, 2σ
50 / 200 cross
Death
0.39 vs 0.58
Trend bias
Below 200
-36.36%
Risk profile
Beta vs SPY
1.23
More volatile than market
Correlation to SPY
0.20
Largely independent
Realised vol 30D
89.2%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-68.8%
Peak to trough
Max drawdown 5Y
-96.8%
Peak to trough
ATR 14
0.04
10.02% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
CTSO: CytoSorbents Future Value Drivers Support Price Target of $4.00
Zacks Small Cap Research · 6d ago
Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript
Motley Fool · 9d ago
Cytosorbents Corporation Q2 2026 Earnings Call Summary
Moby · 15d ago
CytoSorbents Corp (CTSO) (Q2 2026) Earnings Call Highlights: Nearing Breakeven with Strong ...
GuruFocus.com · 16d ago
CytoSorbents: Q2 Earnings Snapshot
Associated Press · 16d ago
CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
PR Newswire · 16d ago
CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights
PR Newswire · 34d ago
OTC Markets Life Sciences Investor Forum: Dr. Phillip Chan, CEO, and Pete Mariani, CFO, of CytoSorbents with Zacks SCR’s Tom Kerr, CFA
Zacks Small Cap Research · 46d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.